Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on developing microglia-based treatments for neurodegenerative diseases, has announced its participation in the Guggenheim Healthcare Innovation Conference. The company's management will engage in a fireside chat on November 11, 2024, at 10:30 a.m. ET. A live webcast will be available for registration and can be accessed through the company's website under the Investors section. The recorded session will remain accessible for approximately 90 days after the event.
Vigil Neuroscience (Nasdaq: VIGL), una società di biotecnologie in fase clinica focalizzata sullo sviluppo di trattamenti basati sulle microglia per le malattie neurodegenerative, ha annunciato la sua partecipazione alla Guggenheim Healthcare Innovation Conference. La direzione dell'azienda parteciperà a un incontro informale il 11 novembre 2024, alle 10:30 ET. Sarà disponibile un webcast in diretta per la registrazione, accessibile tramite il sito web dell'azienda nella sezione Investitori. La registrazione della sessione rimarrà accessibile per circa 90 giorni dopo l'evento.
Vigil Neuroscience (Nasdaq: VIGL), una empresa de biotecnología en etapa clínica centrada en el desarrollo de tratamientos basados en microglía para enfermedades neurodegenerativas, ha anunciado su participación en la Guggenheim Healthcare Innovation Conference. La dirección de la empresa participará en una charla informal el 11 de noviembre de 2024, a las 10:30 a.m. ET. Se podrá registrar para un webcast en vivo, que estará disponible a través del sitio web de la empresa en la sección de Inversores. La sesión grabada permanecerá accesible durante aproximadamente 90 días después del evento.
Vigil Neuroscience (Nasdaq: VIGL)는 신경퇴행성 질환을 위한 미세아 교세포 기반 치료 개발에 주력하는 임상 단계 생명공학 회사로, 구겐하임 헬스케어 혁신 회의에 참여할 것이라고 발표했습니다. 회사 경영진은 2024년 11월 11일 오전 10시 30분(ET)에 화기애애한 대화에 참여할 예정입니다. 생중계 웹캐스트는 등록 가능하며, 회사 웹사이트의 투자자 섹션을 통해 접근할 수 있습니다. 녹화된 세션은 이벤트 이후 약 90일 동안 접근할 수 있습니다.
Vigil Neuroscience (Nasdaq: VIGL), une entreprise de biotechnologie en phase clinique axée sur le développement de traitements basés sur les microglies pour les maladies neurodégénératives, a annoncé sa participation à la Guggenheim Healthcare Innovation Conference. La direction de l'entreprise participera à une discussion informelle le 11 novembre 2024 à 10h30 ET. Un webinaire en direct sera disponible pour l'enregistrement et pourra être consulté sur le site web de l'entreprise dans la section Investisseurs. La session enregistrée restera accessible pendant environ 90 jours après l'événement.
Vigil Neuroscience (Nasdaq: VIGL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von mikrogliabasierten Therapien für neurodegenerative Erkrankungen konzentriert, hat seine Teilnahme an der Guggenheim Healthcare Innovation Conference bekannt gegeben. Das Management des Unternehmens wird am 11. November 2024 um 10:30 Uhr ET an einem informellen Gespräch teilnehmen. Ein Live-Webcast wird zur Registrierung verfügbar sein und kann über die Unternehmenswebsite im Bereich Investoren aufgerufen werden. Die aufgezeichnete Sitzung wird voraussichtlich 90 Tage nach der Veranstaltung zugänglich bleiben.
- None.
- None.
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 11, 2024, at 10:30 a.m. ET.
To register for the live webcast, please click here. The webcast will also be available on the Company’s website in the “Investors” section under “Events & Presentations.” An archived webcast will be available for approximately 90 days following the event. .
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) patients, including some who carry TREM2 and other disease-associated variants.
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com
Media Contact:
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com
FAQ
When is Vigil Neuroscience (VIGL) presenting at the Guggenheim Healthcare Innovation Conference 2024?
How long will the Vigil Neuroscience (VIGL) Guggenheim Conference webcast be available?
What type of presentation will Vigil Neuroscience (VIGL) give at the Guggenheim Healthcare Conference?
Where can investors access the Vigil Neuroscience (VIGL) Guggenheim Conference presentation?
